Boston biotech Zafgen shares down after patient dies in obesity drug trial
Shares of Zafgen plunged today after the small biotech firm said a patient in a late-stage trial of its experimental drug to treat obesity has died.
In a statement, the company said that "Zafgen (Nasdaq: ZFGN) recently learned of a patient death which occurred in the company’s ongoing double-blind, randomized, placebo-controlled Phase 3 best PWS study of beloranib in Prader-Willi Syndrome, a rare genetic disorder with a high rate of mortality linked to obesity and its co-morbidities. The cause…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Don Seiffert Source Type: news
More News: Biotechnology | Eating Disorders & Weight Management | Genetics | Health | Health Management | Obesity | Prader-Willi Syndrome | Study